Juventas Therapeutics, Inc.
Edit

Juventas Therapeutics, Inc.

http://juventasinc.com/
Tags:BioTechBodyClinicDevelopmentGrowthHealthTechOwnProductResearch
Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently enrolling a Phase 2b study in patients with advanced peripheral artery disease.
Location: United States, Ohio, Cleveland
Member count: 11-50
Total raised: $35.7M
Founded date: 2007
Facebook
LinkedIn
Email

Investors 2

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
13.05.2015-$13.5M-medcitynew...
16.07.2012Series B$22.2M-finsmes.co...

Mentions in press and media 22

DateTitleDescriptionCategoryAuthorSource
25.10.2021Juventas C...Juventas has grabbed a $63 mil...Biotech-fiercebiot...
18.11.2020CASI Pharm... ROCKVILLE, Md. and BEIJING, ...--prnewswire...
13.05.2015Juventas T...Juventas Therapeutics, Inc., a...USA-finsmes.co...
13.05.2015Cleveland ...Juventas has studied JVS-100 i...--medcitynew...
12.05.2015Juventas T... CLEVELAND, OH, Juventas Ther...--vcnewsdail...
19.05.2014Juventas T...STOP-HF Trial of JVS-100 in Pa...-Business W...venturebea...
16.07.2012Juventas T...Juventas Therapeutics, a Cleve...funding U...-finsmes.co...
16.07.2012Juventas T... CLEVELAND, OH, Clinical-stag...--vcnewsdail...
24.05.2011Juventas’ ...Four months after treatment, h...--medcitynew...
27.04.2011Urologix t...Urologix Inc. (NSDQ:ULGX) is h...-MassDevice...massdevice...
Show more